PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
439.10%
EBIT growth above 1.5x TRVN's 14.24%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
10.94%
Operating income growth at 75-90% of TRVN's 14.24%. Bill Ackman would demand a plan to enhance operating leverage.
11.95%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
11.92%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
11.92%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
61.50%
OCF growth above 1.5x TRVN's 37.31%. David Dodd would confirm a clear edge in underlying cash generation.
61.50%
FCF growth above 1.5x TRVN's 37.31%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.75%
Negative 10Y OCF/share CAGR while TRVN stands at 49.15%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-26.75%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-12.80%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-1.77%
Negative 10Y net income/share CAGR while TRVN is at 60.68%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1.77%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-83.78%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-414.12%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-414.12%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-184.96%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.90%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-7.50%
We cut SG&A while TRVN invests at 10.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.